


BROOKS LABORATORIES LIMITED

Regd office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan, H.P.-174101

Statement of Audited Financial Results for the Quarter and Year Ended 31st March, 2013

(Rs. in Lacs)

Sr. No.	Particulars	Quarter Ended			Accounting Year Ended	
		Audited	Unaudited		Audited	
		31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012
1	Income from operations:					
	(a) Net sales	2,230	2,324	1,448	8,011	5,608
	(b) Other operating income	-	-	-	-	-
	Total income from operations (Net)	2,230	2,324	1,448	8,011	5,608
2	Expenses:					
	(a) Cost of materials consumed	1,682	1,628	956	5,678	3,619
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(24)	(10)	(111)	57	28
	(d) Employee benefits expense	44	70	95	174	273
	(e) Depreciation and amortisation expense	20	21	17	81	66
	(f) Other Administrative Expenses	268	363	208	1,052	641
	Total expenses	1,991	2,072	1,165	7,042	4,627
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	240	252	283	969	981
4	Other income	556	52	22	701	92
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	796	303	305	1,670	1,073
6	Finance costs	(17)	(4)	42	11	156
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	812	307	263	1659	917
8	Exceptional items	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 - 8)	812	307	263	1659	917
10	Tax expense					
	-Current Tax	171	61	52	325	183
	-MAT Credit Unutilized	(95)	57	49	48	170
	-Deferred Tax	3	5	10	17	20
11	Profit / (Loss) from ordinary activities before tax (9-10)	543	298	250	1,365	884
	Share of profit / (loss) of associates*	-	-	-	-	-
	Minority interest *	-	-	-	-	-
	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	543	298	250	1,365	884



[Handwritten Signature]

	Paid-up equity share capital (Face Value Rs.10/- per share)	1619	1619	1619	1,619	1,619
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	8,872	7,508
	Earnings per share (before extraordinary items)					
	(a) Basic -in Rs.	4.48	7.33	2.62	8.43	6.55
	(b) Diluted- in Rs.	4.48	7.33	2.62	8.43	6.55
	Earnings per share (after extraordinary items)					
	(a) Basic -in Rs.	4.48	7.33	2.62	8.43	6.55
	(b) Diluted- in Rs.	4.48	7.33	2.62	8.43	6.55
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	-Number of shares	6,350,000	6,350,000	6,350,000	6,350,000	6,350,000
	-Percentage of shareholding	39.23	39.23	39.23	39.23	39.23
2	Promoters and Promoter Group Shareholding					
	a) Pledged / Encumbered					
	-Number of shares	0	0	0	0	0
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0	0
	-Percentage of shares (as a % of the total share capital of the company)	0	0	0	0	0
	b) Non - encumbered					
	-Number of shares	9,836,422	9,836,422	9,836,422	9,836,422	9,836,422
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100
	-Percentage of shares (as a % of the total share capital of the company)	60.77	60.77	60.77	60.77	60.77
B	INVESTOR COMPLAINTS					
						Quarter ended 31.03.2013
	Pending at the beginning of the quarter					0
	Received during the quarter					0
	Disposed of during the quarter					0
	Remaining unresolved at the end of the quarter					0

Handwritten signature



BROOKS LABORATORIES LIMITED

Regd office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan, H.P.-174101

(Rs.in lacs)

Statement of Assets and Liabilities		Audited	
		As at (31/03/2013)	As at (31/03/2012)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	1,619	1,619
	(b) Reserves and surplus	8,872	7,508
	Sub-total - Shareholders' funds	10,491	9,127
2	Share application money pending allotment		
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	138	121
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	56	49
	Sub-total - Non-current liabilities	194	170
5	Current liabilities		
	(a) Short-term borrowings	109	99
	(b) Trade payables	1,285	724
	(c) Other current liabilities	313	113
	(d) Short-term provisions	821	443
	Sub-total - Current liabilities	2,528	1,379
	TOTAL - EQUITY AND LIABILITIES	13,213	10,676
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	5,617	5,601
	(b) Non-current investments	2	2
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	672	593
	(e) Other non-current assets	329	327
	Sub-total - Non-current assets	6,620	6,523
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	498	516
	(c) Trade receivables	2,168	1,076
	(d) Cash and cash equivalents	2,387	1,964
	(e) Short-term loans and advances	40	141
	(f) Other current assets	1,500	457
	Sub-total - Current assets	6,593	4,154
	TOTAL - ASSETS	13,213	10,676

Handwritten signature



Statement of Utilization of funds raised through public issue as on 31st March 2013.

(Rs. in Lacs)

Sr.No.	Object	Total Estimated Cost	Actual Utilizations
1	Land	635.00	562.40
2	Building Construction	1,220.00	1,200.00
3	Plant & Machinery & Utilities	3,094.00	1,527.00
4	Advance given for Purchase of Misc. Fixed Assets	230.00	200.00
5	Long term working capital	500.00	NIL
6	General corporate purposes	328.29	87.91
7	Listing Fees to Stock Exchanges	0.96	0.96
8	Issue Expenses	291.75	291.75
	Total	6,300.00	3870.02

[Handwritten Signature]



Notes:

- 1) The above result for the period ended 31st March 2013, as reviewed by the Audit Committee, and were considered and approved by the Board of Directors at its meeting held on 29^h May 2013.
- 2) As the company's business activity falls within a single primary business segment "Pharmaceutical Formulations" the Disclosure Requirement of Accounting Standard (AS-17) "Segment Reporting" is not applicable.
- 3) The figures for the corresponding previous periods have been restated/regrouped wherever necessary, to make them comparable. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the current financial year, which were subject to limited review.

Place: MUMBAI

Date: 29th May 2013

FOR BROOKS LABORATORIES LIMITED



A handwritten signature in black ink, appearing to read "Rajesh Mahajan".

MR. RAJESH MAHAJAN

MANAGING DIRECTOR